You are here

  • Home
  • Archive
  • Volume 4, Issue 1
  • High-dose interleukin2 – a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome

Article metrics

Article menu

Download PDFPDF

Short Report
High-dose interleukin2 – a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome

 

Online download statistics by month:

Online download statistics by month: January 2020 to March 2024

AbstractFullPdf
Jan 2020330
Feb 2020773
Mar 202014142
Apr 2020881
May 202019195
Jun 202012121
Jul 2020550
Aug 20204421
Sep 202025252
Oct 202024242
Nov 202012122
Dec 2020770
Jan 2021441
Feb 2021223
Mar 2021990
Apr 202110102
May 2021772
Jun 2021990
Jul 202110100
Aug 2021441
Sep 202110100
Oct 202113132
Nov 202111111
Dec 202114143
Jan 202230312
Feb 2022551
Mar 2022667
Apr 202210114
May 202225273
Jun 202226282
Jul 202218192
Aug 202219194
Sep 2022181812
Oct 202220201
Nov 2022115713
Dec 2022771
Jan 202311111
Feb 202384841
Mar 202312124
Apr 202310101
May 2023882
Jun 2023220
Jul 202313139
Aug 202310102
Sep 2023660
Oct 2023551
Nov 2023661
Dec 202319196
Jan 20249104
Feb 2024551
Mar 2024992
Total647701141